Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Arcus Biosciences Q1 EPS $(1.14) Misses $(1.02) Estimate, Sales $28.00M Miss $36.54M Estimate

Author: Benzinga Newsdesk | May 06, 2025 03:32pm
Arcus Biosciences (NYSE:RCUS) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.02) by 11.76 percent. This is a 2180 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $28.00 million which missed the analyst consensus estimate of $36.54 million by 23.37 percent. This is a 80.69 percent decrease over sales of $145.00 million the same period last year.

Posted In: RCUS


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist